HealthPulse Analysis.
Original research, benchmarking and policy engagement. Every item is classified by what it establishes, what it suggests, and what it does not prove.
Europe's CAR-T payment terms, read from the hospital's side
HealthPulse Analysis, October 2026, Rene Castillo. Italy, Spain, Germany, France, England and the U.S. CGT Access Model read from the treatment center's side: who pays whom, when, on what evidence, and who carries the risk.
FY2027: why an outlier CAR-T case is paid less
HealthPulse Analysis, September 2026, Rene Castillo. For a CAR-T case above the outlier threshold in both years, FY2027 pays $3,316 less at the same cost. The calculation, its CMS sources and its limits.
The CAR-T Reimbursement Gap: A 2026 Benchmark Analysis
Benchmark research. FY2026 Medicare reimbursement against documented CAR-T delivery costs, drawn from CMS, KFF and peer-reviewed sources.
HealthPulse's Comment to CMS
Regulatory comment. A submitted public comment on Medicaid community engagement requirements and Cell and Gene Therapy Access Model continuity. Not an adopted CMS position.
Reimbursement Breaks First. Access Breaks Next.
Working thesis. HealthPulse's framework on the relationship between reimbursement divergence and downstream access risk.
Research that applies to your program?
The full benchmark report and the complete CMS comment letter are both available on request.
Discuss a decision